MoonLake Immunotherapeutics' Spine Disease Treatment Shows Improvement in a Phase 2 Study

MT Newswires Live02-23 16:56

MoonLake Immunotherapeutics (MLTX) said Sunday that a mid-stage clinical trial of its experimental drug, SLK, for patients with axial spondyloarthritis, a chronic inflammatory disease that affects the spine and joints, showed significant improvement in symptoms.

The drugmaker said 81% of the 26 patients receiving SLK experienced significant symptom improvement after 12 weeks of treatment.

More than 80% of participants also showed meaningful reductions in overall disease activity, the company said. It added that imaging scans revealed reduced inflammation in patients' joints, including deeper tissues that are often difficult to treat.

The company said additional scans suggested the drug may help slow bone changes that can lead to permanent stiffness and joint damage.

As of Dec. 31, the company reported $394 million in cash and short-term investments, which it expects will fund operations into H2 2027.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613200796?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-23 16:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613200796","market":"hk","top_or_hot":-1,"title":"MoonLake Immunotherapeutics' Spine Disease Treatment Shows Improvement in a Phase 2 Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> (MLTX) said Sunday that a mid-stage clinical trial of its experimental drug, SLK, for patients with axial spondyloarthritis, a chronic inflammatory disease that affects the spine and joints, showed significant improvement in symptoms.</p><p>The drugmaker said 81% of the 26 patients receiving SLK experienced significant symptom improvement after 12 weeks of treatment.</p><p>More than 80% of participants also showed meaningful reductions in overall disease activity, the company said. It added that imaging scans revealed reduced inflammation in patients' joints, including deeper tissues that are often difficult to treat.</p><p>The company said additional scans suggested the drug may help slow bone changes that can lead to permanent stiffness and joint damage.</p><p>As of Dec. 31, the company reported $394 million in cash and short-term investments, which it expects will fund operations into H2 2027.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MoonLake Immunotherapeutics' Spine Disease Treatment Shows Improvement in a Phase 2 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMoonLake Immunotherapeutics' Spine Disease Treatment Shows Improvement in a Phase 2 Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-23 16:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> (MLTX) said Sunday that a mid-stage clinical trial of its experimental drug, SLK, for patients with axial spondyloarthritis, a chronic inflammatory disease that affects the spine and joints, showed significant improvement in symptoms.</p><p>The drugmaker said 81% of the 26 patients receiving SLK experienced significant symptom improvement after 12 weeks of treatment.</p><p>More than 80% of participants also showed meaningful reductions in overall disease activity, the company said. It added that imaging scans revealed reduced inflammation in patients' joints, including deeper tissues that are often difficult to treat.</p><p>The company said additional scans suggested the drug may help slow bone changes that can lead to permanent stiffness and joint damage.</p><p>As of Dec. 31, the company reported $394 million in cash and short-term investments, which it expects will fund operations into H2 2027.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2613200796","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613200796","pubTimestamp":1771836964,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"MoonLake Immunotherapeutics  said Sunday that a mid-stage clinical trial of its experimental drug, SLK, for patients with axial spondyloarthritis, a chronic inflammatory disease that affects the spine and joints, showed significant improvement in symptoms.The drugmaker said 81% of the 26 patients receiving SLK experienced significant symptom improvement after 12 weeks of treatment.More than 80% of participants also showed meaningful reductions in overall disease activity, the company said. It added that imaging scans revealed reduced inflammation in patients' joints, including deeper tissues that are often difficult to treat.The company said additional scans suggested the drug may help slow bone changes that can lead to permanent stiffness and joint damage.As of Dec. 31, the company reported $394 million in cash and short-term investments, which it expects will fund operations into H2 2027.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MLTX":"MoonLake Immunotherapeutics"},"translate_title":"MoonLake Immunotherapeutics的脊柱疾病治疗在2期研究中显示出改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLTX":1.5},"content_text":"MoonLake Immunotherapeutics (MLTX) said Sunday that a mid-stage clinical trial of its experimental drug, SLK, for patients with axial spondyloarthritis, a chronic inflammatory disease that affects the spine and joints, showed significant improvement in symptoms.The drugmaker said 81% of the 26 patients receiving SLK experienced significant symptom improvement after 12 weeks of treatment.More than 80% of participants also showed meaningful reductions in overall disease activity, the company said. It added that imaging scans revealed reduced inflammation in patients' joints, including deeper tissues that are often difficult to treat.The company said additional scans suggested the drug may help slow bone changes that can lead to permanent stiffness and joint damage.As of Dec. 31, the company reported $394 million in cash and short-term investments, which it expects will fund operations into H2 2027.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613200796","isCrawlerRequest":true}